» Articles » PMID: 22184756

The Fibrillogenic L178H Variant of Apolipoprotein A-I Forms Helical Fibrils

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2011 Dec 21
PMID 22184756
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

A number of amyloidogenic variants of apoA-I have been discovered but most have not been analyzed. Previously, we showed that the G26R mutation of apoA-I leads to increased β-strand structure, increased N-terminal protease susceptibility, and increased fibril formation after several days of incubation. In vivo, this and other variants mutated in the N-terminal domain (residues 26 to ∼90) lead to renal and hepatic accumulation. In contrast, several mutations identified within residues 170 to 178 lead to cardiac, laryngeal, and cutaneous protein deposition. Here, we describe the structural changes in the fibrillogenic variant L178H. Like G26R, the initial structure of the protein exhibits altered tertiary conformation relative to wild-type protein along with decreased stability and an altered lipid binding profile. However, in contrast to G26R, L178H undergoes an increase in helical structure upon incubation at 37°C with a half time (t(1/2)) of about 12 days. Upon prolonged incubation, the L178H mutant forms fibrils of a diameter of 10 nm that ranges in length from 30 to 120 nm. These results show that apoA-I, known for its dynamic properties, has the ability to form multiple fibrillar conformations, which may play a role in the tissue-specific deposition of the individual variants.

Citing Articles

Apolipoprotein A-I priming via SR-BI and ABCA1 receptor binding upregulates mitochondrial metabolism to promote insulin secretion in INS-1E cells.

Lyons C, Cowan E, Nilsson O, Mohar M, Pena-Martinez P, Eliasson L PLoS One. 2024; 19(11):e0311039.

PMID: 39546458 PMC: 11567530. DOI: 10.1371/journal.pone.0311039.


The APOA1 p.Leu202Arg variant potentially causes autosomal recessive cardiac amyloidosis.

Yagi S, Miyamoto R, Tasaki M, Morino H, Otani R, Kadota M Hum Genome Var. 2024; 11(1):30.

PMID: 39152105 PMC: 11329782. DOI: 10.1038/s41439-024-00288-7.


The Apparent Organ-Specificity of Amyloidogenic ApoA-I Variants Is Linked to Tissue-Specific Extracellular Matrix Components.

Del Giudice R, Lindvall M, Nilsson O, Monti D, Lagerstedt J Int J Mol Sci. 2023; 24(1).

PMID: 36613763 PMC: 9820410. DOI: 10.3390/ijms24010318.


Autophagy Alteration in ApoA-I Related Systemic Amyloidosis.

Del Giudice R, Imbimbo P, Pietrocola F, Martins I, De Palma F, Bravo-San Pedro J Int J Mol Sci. 2022; 23(7).

PMID: 35408859 PMC: 8998969. DOI: 10.3390/ijms23073498.


Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis.

Lee C, Liao C, Meng S, Wu W, Chiang J, Wu M Biomedicines. 2021; 9(8).

PMID: 34440189 PMC: 8393881. DOI: 10.3390/biomedicines9080985.


References
1.
Alexander E, Tanaka M, Kono M, Saito H, Rader D, Phillips M . Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. J Lipid Res. 2009; 50(7):1409-19. PMC: 2694339. DOI: 10.1194/jlr.M800578-JLR200. View

2.
Di Gaetano S, Guglielmi F, Arciello A, Mangione P, Monti M, Pagnozzi D . Recombinant amyloidogenic domain of ApoA-I: analysis of its fibrillogenic potential. Biochem Biophys Res Commun. 2006; 351(1):223-8. DOI: 10.1016/j.bbrc.2006.10.026. View

3.
Westermark P, Sletten K, Johansson B, CORNWELL 3rd G . Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990; 87(7):2843-5. PMC: 53787. DOI: 10.1073/pnas.87.7.2843. View

4.
Anantharamaiah G, Jones J, Brouillette C, Schmidt C, Chung B, Hughes T . Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem. 1985; 260(18):10248-55. View

5.
Lepedda A, Cigliano A, Cherchi G, Spirito R, Maggioni M, Carta F . A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis. 2008; 203(1):112-8. PMC: 2659534. DOI: 10.1016/j.atherosclerosis.2008.07.001. View